Introduction
FXII is the initiator of the intrinsic coagulation cascade and can be activated via contact with charged surfaces to form FXIIa, which then activates FXI and plasma kallikrein. Plasma kallikrein can activate FXII in a reciprocal manner to further amplify contact activation (Renne and Gailani, 2007; Renne et al., 2012; Bjorkqvist et al., 2014) .
Although human genetics and epidemiological studies to date do not yield a clear relationship between FXII deficiency and risk of thrombosis, FXII deficiency in humans is not associated with bleeding diathesis, despite marked aPTT prolongation (Lammle et al., 1991; Renne and Gailani, 2007) . FXII knockout (KO) mice were protected from arterial thrombosis, ischemic stroke, and deep vein thrombosis, while maintaining normal hemostasis (Renne et al., 2005; Kleinschnitz et al., 2006; Muller et al., 2009; von Bruhl et al., 2012) , suggesting that FXII is critically involved in pathological thrombus formation but dispensable for hemostasis. Emerging studies also suggest that FXII is a key mediator in host defense and additional immune-inflammatory responses, via its downstream kallikrein/kinin system (KKS) (Schmaier, 2016) and interactions with endothelial and immune cells (Gobel et al., 2016; Long et al., 2016) . FXII is thus a promising target for treating not only thrombotic events but also a range of other disorders (Martini et al., 2014; Gobel et al., 2016; Hopp et al., 2016; Nickel et al., 2016; Zamolodchikov et al., 2016) without conferring a bleeding risk.
In recent years, inhibitors for FXII(a) have been generated and described in various preclinical models in vitro or in vivo. These agents include monoclonal antibodies (Larsson et al., 2014; Matafonov et al., 2014) , natural peptide or protein inhibitors (Hagedorn et al., 2010; Yau et al., 2012) , small molecule inhibitors JPET #238493 (Kleinschnitz et al., 2006; Baeriswyl et al., 2015) , RNA aptamer (Woodruff et al., 2013) , siRNA (Cai et al., 2015) , and antisense oligonucleotide (ASO) (Revenko et al., 2011) .
While results with these various tool molecules in aggregate strengthen the notion that targeting FXII may provide benefit in a range of disease settings, some of the small molecule or peptide inhibitors utilized in generating in vivo data have insufficient selectivity (Hansson et al., 2014; Korneeva et al., 2014; Xu et al., 2014) , hampering the precise understanding on target-based pharmacology. Despite the difficulty in achieving the required target selectivity and potency using a small molecule inhibitor, this modality potentially maintains favorable attributes such as oral bioavailability and shorter pharmacokinetics unavailable in certain other therapeutic classes. As small molecule drugs need to balance between potency, selectivity, and pharmaceutical properties (e.g. permeability and bioavailability), understanding levels of target engagement (e.g. enzyme occupancy, residence time) needed for efficacy is an important component in establishing chemical tractability of the target. The monoclonal antibody modality, while likely carrying a superior selectivity profile, is mechanistically distinct from small molecule inhibitors and is limited in applicable patient settings due to its parenteral route of administration.
It has been observed that FXIIa can be localized to thrombi and can directly interact with fibrin thereby potentially modulating clot structure and thrombus stability (Konings et al., 2011; Kuijpers et al., 2014) . While FXII inhibition or loss of function markedly reduces thrombus formation in various models and species, thrombi in FeCl 3injured mesenteric vessels of FXII KO mice appeared unstable and prone to embolization in intravital microscopy studies (Renne et al., 2005) , and FXIIa inhibitor treatment has JPET #238493 Tris with 3 M NaCl, pH 8.5. The purified protein was buffer-exchanged into Dulbecco's modified PBS (pH 7.0) and analyzed by SDS-PAGE and Western blot with HA antibody (Abcam, Cambridge, MA, USA) for confirmation.
In vitro protease inhibition assays
Human FXIIa, plasma kallikrein, thrombin, aPC, and plasmin were purchased from Enzyme Research Laboratories (South Bend, IN, USA). Human FVIIa, FXIa, and Xa were purchased from Sekisui Diagnostics (Lexington, MA, USA). Human FIXa was purchased from Haematologic Technologies (Essex Junction, VT, USA). Recombinant human tissue plasminogen activator (tPA) was purchased from Hyphen Biomed, S.A.S.
(Neuville-sur-Oise, France). Cynomolgus macaque and rabbit FXIIa were prepared by Evotec (US), Inc (Princeton, NJ, USA). The 7-amido-4-thifluoromethylcoumarin (AFC) containing fluorescence substrate, CH 3 SO 2 -cyclohexyl-Gly-Gly-Arg-AFC (cyclohexyl-G-G-R-AFC) was custom synthesized by CPC Scientific (Sunnyvale, CA, USA), while substrates N-CBZ-Gly-Pro-Arg-AFC (Z-G-P-R-AFC), and n-acetyl-Gly-Pro-Arg-AFC (Acetyl-K-P-R-AFC) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
All enzymatic reactions were carried out in 50 mM HEPES, 150 mM NaCl, 5 mM CaCl 2 , and 0.1% PEG (8000 NMW), at pH 7.4 and 25°C. The change in fluorescence during reaction progression was monitored using a Tecan m200 plate reader in kinetic mode set at 405 nm excitation and 500 nm emission with 9 and 20 nm bandwidths, respectively. For all enzymes tested except FXIIa the slope of the fluorescence versus time plots was determined by linear regression and plotted versus rHA-Mut-inf concentration to determine IC 50 , which was subsequently converted to K I using the Cheng-Prusoff equation. For rHA-Mut-inf and rHA-WT-inf inhibition of human FXIIa, JPET #238493 K I and binding kinetic parameters (k on and k off ) were determined using global progress curve analysis for 1-step slow and tight binding (Zhang and Windsor, 2013) . Additional characterization of human, cynomolgus macaque, and rabbit FXIIa activity was performed following a 2 hr pre-incubation of the enzyme with either rHA-WT-inf or rHA-Mut-inf to enable the enzyme-rHA-inf complex to reach equilibrium and analyzed using global progress curve analysis for tight binding.
Plasma Shift Studies
For plasma shifts studies, standard FXIIa enzymatic assays were performed as above described except that either human, cynomolgus, or rabbit FXIIa was preincubated with rHA-Mut-Inf in either the absence or presence of either human, cynomolgus, or rabbit 30% heat-inactivated plasma for 2 hours prior to initiation of the reaction by the addition of substrate. It has been determined that the 30% heat-inactivated plasma retains protein binding activity but is no longer activatable for the endogenous coagulation machinery (not shown). Fluorescence versus time plots were analyzed from global progress curve analysis for 1-step fast and tight binding (Zhang and Windsor, 2013) .
To determine the percent unbound concentration of rHA-Mut-inf in 100 % Plasma, % Free, the following equation was used:
Where % Plasma Target is the target percent plasma (100% in these studies), % Plasma Assay is the percent plasma used in the assay (30% in these studies) and − % is the plasma shifted K I .
Surface plasmon resonance
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For surface plasmon resonance (SPR) experiments rHA-Mut-inf was immobilized to a standard CM3 sensor chip (GE Healthcare, Piscataway, NJ, USA) using the Amine Coupling Kit and the supplied pH 5.0 sodium acetate buffer to a density of ~2000 RU.
Kinetics of binding of FXIIa and FXII zymogen were monitored using the single cycle kinetic method. Running buffer was 10 mM HEPES sodium salt, 150 mM NaCl, 5 mM CaCl 2 , 0.005 % P-20 at pH 7.4. Solutions of FXIIa and FXII at 0.1, 1, 10, 30, and 100 nM were sequentially injected at a flow rate of 25 µL/min for 240 seconds each. Dissociation was monitored for 3600 seconds following the last injection. Data was analyzed using the 1:1 interaction model and the heterologous ligand model in the BIAcore analysis software.
Both fits yielded similar results for the dominant binding event.
Activated partial thromboplastin time (aPTT), prothrombin time (PT), thrombin generation assay (TGA), and thromboelastography (TEG) assay
In vitro and ex vivo activated partial thromboplastin time (aPTT, triggered by aPTT-XL, Pacific Hemostasis, Middletown, VA, USA ) and prothrombin time (PT, triggered by TriniCLOT PT Excel, Tcoag, Bray, Ireland) were measured as described before (Xu et al., 2014; Cai et al., 2015) .
TGA triggered by 0.83 µM ellagic acid (r2 Diagnostics, South Bend, IN, USA) was performed using standard methods as reported earlier (Xu et al., 2014; Cai et al., 2015) . Briefly, rHA-Mut-inf at different concentrations was spiked into 60 µL citrated plasma (human or cynomolgus or rabbit) and incubated at 37°C for 1 hour; 15 µL trigger was then added to the plasma and incubated for an additional 10 minutes at 37°C. 15 µL of FluCa was subsequently injected into the samples to initiate thrombin generation.
Thrombinoscope software was used to calculate peak thrombin as well as additional 9 JPET #238493 parameters (lag time, ETP (endogenous thrombin potential), time to peak (ttpeak), and slope (peak divided by the difference between lag and ttpeak)).
TEG analysis was carried out on the thromboelastograph coagulation analyzer model 5000 (Haemonetics, Braintree, MA, USA) as reported earlier .
Briefly, rHA-WT-inf or rHA-Mut-inf at various concentrations was spiked into freshly collected citrated human whole blood and incubated at room temperature for 10 minutes.
340 µL of the blood sample was then transferred into the TEG sample cup preloaded with 20 µL Ca, 3.4 µL ellagic acid, and 1 µL tPA, gently mixed, with the TEG recording initiated right after. The final concentration of ellagic acid in the reaction system was 0.031 µM. Final concentration of tPA in the reaction system was 1.5 nM and this concentration of tPA had been pre-characterized as effectively eliciting a fibrinolysis phase in the donor's blood sample without apparently affecting the coagulation parameters (not shown). R (reaction time), Ly60 (% lysis at 60 minutes post MA) and additional parameters were recorded by the machine and analyzed.
Rabbit microembolic signals (MES) studies
Male New Zealand White rabbits (weighing 2.4-3.0 kg, 10-13 weeks of age, obtained from Charles River Canada), were used for the current studies. All the procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health, and approved by the Animal Care and Use Committee of Merck & Co., Inc., Kenilworth, NJ USA.
The rabbit model of cerebral MES was induced by FeCl 3 injury of the carotid artery as described in detail previously (Zhou et al., 2016a; Zhou et al., 2016b) . Briefly, 10 This article has not been copyedited and formatted. The final version may differ from this version. 
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animals were anesthetized with a cocktail (50 mg/kg ketamine HCl, Pfizer Inc., and 5 mg/kg xylazine, LLOYD Inc., IM) as a non-recovery procedure. The left common carotid artery (CCA) was surgically exposed. A Doppler flow probe (Model 1.5 or 2.0 PRB, Transonic Systems, Ithaca, NY, USA) connected to a flow meter (Model T403, Transonic Systems) was used to measure the artery blood flow with continuous data acquisition by a PowerLab 16/35 and LabChart Pro system (AD Instruments, Colorado Springs, CO, USA). Thrombosis was induced by applying two pieces of filter papers (7.4 mm in diameter, 0.5 mm thick each, above and beneath the vessel; Life Technologies, Grand Island, NY, USA) pre-saturated with 30% FeCl3 (Anhydrous 98%, Cat# 169430050, ACROS Organics/Thermo Fisher Scientific, Waltham, MA, USA) to the adventitial surface of the vessel. A piece of para-film was put underneath the vessel to protect the surrounding tissue from injury. The filter papers were removed after 5 min followed by washout of residue FeCl3 with warm saline. The blood flow was monitored for 60 min from the time of FeCl3 application (as time zero). Integrated carotid blood flow over 60 min was quantitated using area under the curve (AUC), calculated by the trapezoidal rule, and expressed as percent of control blood flow as described previously (Wong et al., 2008; Zhou et al., 2016b) . At end of study (i.e., 60 min after FeCl 3 injury), the wet thrombus weight was measured using a balance with a detection limit of 0.001 mg of the rabbits, at an angle of ~80 degree against the buccal surface. The MCA was insonated at a depth between 19 to 22 mm as described in details previously (Zhou et al., 2016a) . MES (defined as High Intensity Transient Signals, HITS) was saved and further validated based on the criteria defined by the International Consensus Committee as described previously (Ringelstein et al., 1998; Zhou et al., 2016a; Zhou et al., 2016b) .
Vehicle (10 mM phosphate buffer, pH 7.0) or various doses of rHA-Mut-inf (0.1-1.0 mg/kg) were administrated at 2 mL/kg, bolus, through the ear vein 20 min prior to the FeCl 3 injury. Doses for rHA-Mut-inf were selected based on its comparable potency to rHA-WT-inf in vitro and in our pilot in vivo studies (not shown), and the potency of rHA-WT-inf in our previous studies in rabbits (Xu et al., 2014) .
Ex vivo measurement of rHA-Mut-inf plasma concentrations and clotting time assays
Plasma levels of rHA-Mut-inf were measured by a standard liquid chromatography/mass spectrometry (LC/MS) method as reported earlier (Xu et al., 2014) based on the peptide sequence of Mut-inf (Inf4mut15) (Campos et al., 2012) .
Ex vivo plasma activated partial thromboplastin time (aPTT) and prothrombin time (PT) were determined by standard methods using aPTT-XL (Pacific Haemostasis, Waltham, MA, USA) and TriniCLOT PT Excel (Tcoag, Bray, Ireland) on a KC4 Delta coagulation analyzer (Tcoag, Bray, Ireland).
Statistical analysis
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Data are presented as mean ± standard error (SE), and analyzed using one-way ANOVA followed by Bonferroni post hoc test in GraphPad Prism (Version 7, Graphpad, La Jolla, CA, USA) for comparison among groups with different treatment concentrations or doses. ED50, defined as doses for half-maximal effect, was determined by a non-linear four-parameter dose-response curve fit using GraphPad Prism under the dose ranges described in each figure legend. Results were considered significant when p < 0.05.
Results
rHA-Mut-inf is a highly potent and selective inhibitor of FXIIa
Despite its pM potency for FXIIa inhibition, the original rHA-WT-inf carries offtarget activity on several other coagulation and fibrinolytic factors including inhibitory activity on FXa and plasmin (Campos et al., 2004b; Xu et al., 2014; Kolyadko et al., 2015) . To fully understand the selectivity profile of rHA-Mut-inf we examined its impacts on the enzymatic activities of a comprehensive panel of human and rabbit serine proteases that include coagulation factors, fibrinolytic factors, and trypsin. We chose to determine the apparent inhibition constants (K I ) for all of the enzymes tested (Table 1 and Supplemental Figure 1 ) in order to accurately assess the occupancy of rHA-Mut-inf for these enzymes in various studies. To facilitate a direct comparison of the activity of these enzymes we used similar fluorescently labeled tripeptide substrates for K M determinations. For the human enzymes, no less than 4000-fold selectivity was observed for any off-target human enzyme tested and no less than 3200-fold selectivity was observed for rabbit enzyme. Using the same method, K I for rHA-WT-inf on FXIIa was determined to be 0.12 nM (Supplemental Figure 2) . rHA-Mut-inf is thus comparable to 13 This article has not been copyedited and formatted. The final version may differ from this version. 
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rHA-WT-inf for on-target (FXIIa-inhibitory) activity and is much more selective than rHA-WT-inf against other serine proteases.
Mode of action of rHA-Mut-inf
Fig . 1A shows the inhibitory effects of rHA-Mut-inf on the human FXIIamediated cleavage of a fluorescent substrate. As has been previously (Xu et al., 2014) described for rHA-WT-inf, this inhibition is slow to reach equilibrium, and occurs at concentrations of inhibitor less than the concentration of enzyme used for this assay, necessitating taking these factors into account in the analysis of the data to determine the K I . Also, since under the conditions used in this experiment the time to reach equilibrium was slow relative to the data recording timescale, the binding kinetics of the rHA-Mutinf-FXIIa interaction has been elucidated directly from this inhibition study. This slowly evolving inhibition is driven by the long half-life of dissociation of the rHA-Mut-inf-FXIIa complex (t 1/2 = 4.1 h, k off = 4.8 × 10 -5 s -1 ), while the association rate (k on = 6.6 × 10 5 M -1 •s -1 ) is within normal ranges for this type of interaction.
Previous studies (Xu et al., 2014; Kolyadko et al., 2015) demonstrated that the inhibition of rHA-WT-inf was not directed against the zymogen FXII, but solely against the activated form (FXIIa). To confirm the activated enzyme specificity and binding kinetics for rHA-Mut-inf we used surface plasmon resonance (SPR) to kinetically monitor the interactions of FXIIa and FXII zymogen with immobilized rHA-Mut-inf ( Fig.   1B ). Results indicated that rHA-Mut-inf is directed against FXIIa, since no significant binding was observed for zymogen FXII. In addition, kinetic data from SPR (K D = 250 pM, k on = 1.0 × 10 5 M -1 •s -1 , k off = 3.0 × 10 -5 s -1 ) agree well with the binding kinetics determined directly from the inhibition assays. Furthermore, the mode of FXIIa inhibition JPET #238493 for rHA-Mut-inf was characterized using standard enzymatic methods and shown to be peptide substrate competitive (Fig. 1C ). These findings are in accordance with the earlier characterization of rHA-WT-inf mode of inhibition (Xu et al., 2014) and strongly support that the inhibitory effects of these molecules are mediated through their direct interactions with the active site of FXIIa.
Effects of rHA-Mut-inf in aPTT, PT, TGA, and TEG
Functional activity of rHA-Mut-inf was examined in vitro in human, cynomolgus, and rabbit plasma in aPTT and PT assays, as well as in ellagic acid-triggered TGA. rHA-Mut-inf prolonged aPTT in a dose-dependent manner in all 3 species ( Fig. 2A) , with the potency in rabbit far exceeding that in human and cynomolgus. Concentrations needed for doubling aPTT are 19, 8.5, and 0.26 µM, in human, cynomolgus, and rabbit plasma, respectively. In the PT assay (Fig. 2B) , no change in PT was observed at concentrations < 5 µM and a very modest (~10%) PT prolongation was observed in human and cynomolgus plasma at 30 µM. rHA-Mut-inf reduced ellagic acid-triggered thrombin generation in TGA in a dose-dependent manner (Fig. 2C ). IC 50 on peak thrombin is 5.5, 0.69, 0.05 µM in human, cynomolgus, and rabbit plasma, respectively.
Effects of rHA-Mut-inf on blood coagulation and fibrinolysis was also assessed in the whole blood TEG assay (Fig. 3) , in a direct comparison with rHA-WT-inf, as described in Methods. A threshold concentration (1.5 nM) of tPA was present in the assay system to generate a fibrinolysis phase without affecting the clotting phase appreciably. Representative TEG traces of the human blood samples treated with 0 (veh), 1, 2, 4 µM rHA-Mut-inf or rHA-WT-inf are shown in Fig. 3A . Both agents exerted a dose-dependent prolongation on R (Fig. 3B, left panel) , in a similar manner, with rHA-15 This article has not been copyedited and formatted. The final version may differ from this version. 
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Mut-inf being slightly more potent than rHA-WT-inf at the highest concentration tested (4 µM). In contrast, while rHA-WT-inf produced marked and dose-dependent inhibition on tPA-induced fibrinolysis (Ly60), rHA-Mut-inf did not modulate fibrinolysis (Fig. 3B,   right panel) .
Effects of rHA-Mut-inf in plasma shift studies
An essential component of the calculation of target engagement of a therapeutic molecule is its unbound fraction in the compartment of its target. Since coagulation occurs within the plasma, and since rHA-Mut-inf is a large molecule that is intractable for deriving free fraction in plasma via the conventional equilibrium dialysis method, we assessed the impacts of human, cynomolgus, or rabbit heat-inactivated plasma on the observed inhibition of the respective FXIIa protein by rHA-Mut-inf ( Fig. 4 and Table 2) to indirectly determine free fraction in plasma. To minimize the impact of slow-binding by rHA-Mut-inf on the determination of K I , each species FXIIa was preincubated rHA-Mut-inf for 2 hr, enabling FXIIa•rHA-Mut-inf interactions to reach equilibrium prior to reaction initiation with substrate (Supplemental Figure 3) . For each species' plasma, a shift toward lower potency was observed, with the largest shift occurring for human plasma, followed by cynomolgus and the smallest shift observed for rabbit plasma. These shifts were used to estimate the amount of rHA-Mut-inf not bound to plasma proteins and thus available for binding to the target FXIIa (Table 2) . From these values the percent of FXIIa bound to rHA-Mut-inf at steady-state was calculated using the concentration of rHA-Mut-inf that prolonged aPTT by 2-fold. 99.2 % target engagement is needed for doubling aPTT in rabbit plasma while 99.9 % target engagement is needed for doubling aPTT in cynomolgus and human plasma.
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Effects of rHA-Mut-inf in rabbit MES studies
Dose-dependent inhibition of rHA-Mut-inf on both thrombus formation in the carotid artery and MES incidents in the MCA was observed (Fig. 5 ). The integrated blood flow (AUC, illustrated as % of blood flow relative to baseline) was increased from 55.0 ± 5.9% in vehicle group (n=8), to 92.3 ± 1.1% for the 1 mg/kg rHA-Mut-inf, i.v. group (n=6, p<0.01), with ED 50 of 0.174 mg/kg rHA-Mut-inf ( Fig. 5A and B) . Clot weight was reduced from 5.86 ± 0.39 mg (vehicle) to 0.16 ± 0.10 mg (1 mg/kg rHA-Mut-inf, p<0.001), with ED 50 of 0.162 mg/kg rHA-Mut-inf ( Fig. 5C ). (vehicle) to 0.0 ± 0.0 (1 mg/kg rHA-Mut-inf, p<0.01), with ED 50 of 0.057 mg/kg rHA-Mut-inf (Fig. 5E ). The incidence of MES detected in animals was also decreased from 100% (vehicle) to 0% (1 mg/kg rHA-Mut-inf) (Fig. 5F ). Ex vivo aPTT confirmed the pharmacodynamic response for rHA-Mut-inf ( Fig.   6B ). Significant increase in aPTT was observed for 0.3 and 1 mg/kg rHA-Mut-inf dosing groups. Fold aPTT increase at 0.3 and 1 mg/kg (~1.3-fold and ~2.5-fold, respectively) JPET #238493 with their specific drug exposures are highly consistent with the in vitro spike-in study ( Fig. 2A) . A very modest numerical increase in PT post-treatment was observed in all treatment groups including vehicle, with the 0.3 and 1 mg/kg groups reaching statistical significance at 80min (Fig. 6C ).
Pharmacokinetic and pharmacodynamic analysis of rHA-Mut-inf in the rabbit MES model
Discussion
FXII is an emerging promising target for a number of diseases. rHA-WT-inf has been used extensively for interrogating the role of FXII in thrombosis, hemostasis, and additional pathological settings. However, studies from us (Xu et al., 2014) and others (Kolyadko et al., 2015) demonstrated that rHA-WT-inf carries significant off-target activity on FXa and plasmin that may skew its effect on thrombosis and hemostasis in vivo at high concentrations. We were thus interested in exploring alternative FXIIa inhibitors that may carry an improved selectivity profile. Our in vitro enzyme assays (Table 1 ) demonstrated that the human albumin (HA) fusion with Inf4mut15, dubbed as rHA-Mut-inf in this report, has comparable on target effect on FXIIa compared to WT-inf, with higher selectivity against FXa and plasmin, consistent with another report of in vitro characterization of the infestin4 mutants without HA fusion (Kolyadko et al., 2015) . In the whole blood TEG assay, at 1 and 2 µM, rHA-Mut-and WT-inf prolonged clotting time (R) to the same extent while at 4 µM rHA-Mut-inf was more potent; rHA-Mut-inf did not modulate tPA-induced fibrinolysis whereas rHA-WT-inf dose-dependently suppressed fibrinolysis, likely due to its off-target activity on plasmin. It is possible that at the highest dose (4 µM) tested, strong inhibition of plasmin by rHA-WT-inf has dampened its anticoagulant activity, resulting in a lesser prolongation of R compared to rHA-Mut-inf at 4 µM. While the current tPA-induced fibrinolysis TEG may not mimic JPET #238493 all components in vivo by way of which FXIIa modulates fibrinolysis, the system has been previously benchmarked with a number of thrombin inhibitors with results consistent with expectations , and the contrast we observed between rHA-Mut-and WT-inf on fibrinolysis is consistent with their in vitro activity on plasmin in a purified system. Overall, these in vitro results demonstrate that rHA-Mut-inf indeed is a much more selective molecule than rHA-WT-inf, consistent with findings from another group using different methods (Kolyadko et al., 2015) . As potency of rHA-Mutinf exceeds that of 3F7 (a monoclonal antibody inhibitor of FXIIa, K D = 6.2 nM) (Larsson et al., 2014) and FXII618 (a peptide inhibitor of FXIIa, K I = 22 nM) (Baeriswyl et al., 2015) , rHA-Mut-inf is an attractive tool molecule for future research on the role of FXII in vivo in various pathological settings.
With regard to the in vitro aPTT studies, rHA-Mut-inf was much less potent in human and non-human primate plasma as compared to rabbit plasma ( Fig. 2A) . This is consistent with what was observed with 3F7, and with the hypothesis that FXIIindependent activation of FXI may play a more prominent role in primates than in lower species (Gailani et al., 2015) . For the in vitro PT studies, appreciable increases in PT were not observed unless at very high concentrations (20-30 µM) and these PT increases could possibly be due to the residual off-target activity of rHA-Mut-inf on FXa, and/or FIIa, and/or FVIIa (Table 1) . It is therefore important to monitor the actual exposures of rHA-Mut-inf in order to appropriately interpret results of in vivo studies.
With regard to mode of inhibition, our previous analysis (Xu et al., 2014) as well as X-ray crystallography (Campos et al., 2004a; Campos et al., 2012) and docking studies (Kolyadko et al., 2015) with the active proteases suggest that the infestin family of JPET #238493 peptides act as competitive, reversible inhibitors of the active site of the coagulation factors and additional serine proteases. Our kinetics studies with rHA-Mut-inf using the small tri-peptide substrate (Fig. 1) confirmed this notion. Our SPR-based binding studies ( Fig. 1B) further demonstrated that rHA-Mut-inf specifically binds FXIIa but not FXII zymogen. It is therefore unlikely for rHA-Mut-inf to block activation of FXII zymogen to form FXIIa.
As rHA-Mut-inf is a highly selective inhibitor of FXIIa and its mode of inhibition is akin to typical small molecule inhibitors of serine proteases, we were interested in utilizing it in assessing level of target engagement or enzyme occupancy needed for FXIIa for the active site inhibitor mechanism. From drug discovery standpoint, this is a very relevant question, as higher levels of requisite on-target enzyme occupancy will dictate a more stringent selectivity profile and often a higher hurdle on ADME (absorption, distribution, metabolism, excretion) properties of the molecule, especially for an intended oral agent. Using a novel plasma shift assay (Fig. 4) , we first determined the % plasma protein binding (likely mediated by HA) for rHA-Mut-inf across species.
We then selected a putative target of aPTT doubling in calculating enzyme occupancy.
While levels of aPTT prolongation needed for antithrombotic efficacy via targeting FXII in humans are unknown, previous findings with a FXII monoclonal antibody (15H8, targeting heavy chain of FXII) in baboon (Matafonov et al., 2014) suggest that 2X aPTT prolongation is associated with appreciable antithrombotic efficacy in non-human primate and is a reasonable aPTT target, recognizing that aPTT target for translatable efficacy for different modes of inhibition could be different. rabbit plasma was 99.9%, 99.9%, and 99.2%, respectively (Table 2) . This is in contrast with the previous findings that 75% ASO-mediated loss of FXII zymogen (Revenko et al., 2011) or 82% siRNA-mediated loss of FXII zymogen (Cai et al., 2015) was sufficient in delivering robust antithrombotic efficacy in various models in rodents, with the caveat that there could be species difference in target-based pharmacology. The very high level of calculated enzyme occupancy needed for FXIIa active site inhibitors is perhaps unsurprising considering that FXIIa is the most upstream factors in the intrinsic cascade and any "leakage" with a tiny amount of FXIIa may be subsequently cascaded and amplified. One precedent of very high level of target engagement for an active site inhibitor of a coagulation factor is apixaban, a FXa inhibitor, requiring >99% calculated enzyme occupancy in order to deliver clinically relevant efficacy (Ankrom et al., 2016) .
A third potential reason could be that thrombin-mediated activation of FXI will bypass FXII, thus requiring more complete inhibition of FXIIa and immediate shut-down of thrombin generation.
As FXII deficiency confers no bleeding risk, targeting FXII for treatment of ischemic stroke could be a promising strategy. MES has been considered as an independent predictor of stroke or transient ischemic attack (TIA) (Gao et al., 2004; Markus et al., 2005) , and MES originated from the carotid artery is considered as one of the primary sources of stroke in patients (Bonati et al., 2010; Yavin et al., 2011) . Our findings in the rabbit MES study thus provided preclinical evidence in supporting the therapeutic potential of FXIIa inhibition in the treatment and prevention of ischemic stroke and additional thromboembolic disorders. Our findings also strengthened previous reports on beneficial effects of targeting FXII in cerebral ischemia and reperfusion from 21 This article has not been copyedited and formatted. The final version may differ from this version. JPET #238493 different models and species (Kleinschnitz et al., 2006; Krupka et al., 2016) . On the other hand, as more than 2.0X aPTT prolongation was needed to fully restore blood flow in this rabbit MES model ( Fig. 5A and 6B) , more than 99.0% target engagement will be needed, based on our estimate from in vitro analysis (Table 2) . It is to be noted that while our scheme of dosing at 20 minutes prior to vascular injury may ensure adequate and consistent coverage of rHA-Mut-inf during the study based on prior pharmacokinetic study with rHA-WT-inf (Hagedorn et al., 2010) , implications of FXIIa inhibition for stroke prophylaxis may need to be further addressed in studies with tool molecules that can allow more flexible dosing paradigms. Another limitation of our study is that neurological deficits and ischemic brain injury could not be assessed under the current experimental setting (i.e., a non-recovery procedure and with FeCl3 injury of the carotid artery for 60 min to end of study).
In summary, rHA-Mut-inf is a highly potent and selective active site inhibitor of FXIIa. Rabbit MES studies with rHA-Mut-inf suggest that FXIIa inhibition may effectively reduce both thrombus formation and thrombus embolization. However, significant challenges in chemical tractability may exist in developing an oral small molecule drug targeting active site of FXIIa. Alternative strategies and alternative mode of inhibition in targeting FXII thus should be considered. Acetyl-K-P-R-AFC 0.025 0.025 a As described in the legend to Fig 2. rHA-Mut-inf inhibition of FXIIa is time dependent and inhibition constant (K i ) was determined using global analysis of reaction progress curves to determine K i and binding-kinetics parameters. All other enzymatic assays displayed zero-order kinetics in the presence of rHA-Mut-inf and were analyzed using standard methods. b Fold selectivity is the difference in K I of rHA-Mut-inf for the indicated enzyme versus the K I of rHA-Mut-inf for FXIIa from either human or rabbit FXIIa, respectively.
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